MDGL logo Madrigal Pharmaceuticals : MDGL

MDGL

Stock Data

$488.15

Change up

$35.29 (7.79%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Madrigal Pharmaceuticals Inc is a biopharmaceutical company in the clinical stage, primarily focused on creating treatments for non-alcoholic steatohepatitis (NASH), a liver disease. Their main product in development is resmetirom, aimed at treating NASH through a novel approach as a liver-directed thyroid hormone receptor beta agonist. Currently, resmetirom is undergoing Phase 3 clinical trials. The company operates out of West Conshohocken, Pennsylvania.

All Madrigal Pharmaceuticals Articles

9 Articles